Ceres Diagnostics
Ceres Diagnostics is developing a pathogen detection platform that identifies foodborne threats like Salmonella and Listeria by detecting pathogen RNA directly, eliminating the need for DNA amplification used in PCR-based tests. The system uses a proprietary ReBu sample collection solution and an ELISA-compatible form factor, enabling rapid turnaround within a 24-hour critical window at immunoassay-level prices. The technology is designed to integrate seamlessly into existing laboratory workflows and automation platforms.
- Biotechnology
- Food Technology
- Healthcare Technology
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Foodborne pathogens such as Salmonella and Listeria cause millions of illnesses and billions in economic losses annually, yet conventional testing methods are slow and costly. The complexity of modern supply chains amplifies vulnerability, and the food industry faces mounting regulatory scrutiny, reputational risks, and operational disruptions without diagnostics that match the speed of today's marketplace.
Solution
Ceres Diagnostics provides a pathogen detection platform that detects the RNA of target pathogens without needing to amplify DNA like existing PCR-based molecular tests, substantially accelerating response time while reducing costs. Samples are collected into a proprietary "ReBu" solution that degrades pathogen cell walls in food samples and exposes RNA for detection, enabling rapid turnaround at ELISA or immunoassay test prices. The system is highly automatable, increasing lab efficiency and lowering overall testing costs substantially at scale using existing lab workflows and automation platforms for easy adoption. The technology enables early detection within a 24-hour critical window for intervention success.
Target Audience
Primary customers are food testing laboratories, quality assurance teams within food production and processing companies, and environmental testing facilities that require rapid, cost-effective pathogen screening across the supply chain.
Features
- Direct RNA detection technology that eliminates the need for DNA amplification, unlike conventional PCR-based methods
- Proprietary ReBu sample collection solution that degrades pathogen cell walls and exposes RNA for detection
- ELISA-compatible form factor that integrates seamlessly into standard laboratory workflows
- Rapid turnaround time supporting a 24-hour critical window for early intervention success
- Cost-effective testing priced at ELISA or immunoassay levels rather than premium molecular test pricing
- Highly automatable design that increases lab efficiency and lowers testing costs at scale using existing automation platforms